Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEN164 in Children With Autism Spectrum Disorder
NCT05516407Phase 2Completed
- Sponsor
- Fenix Innovation Group
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
A Phase 2 trial of NTI164 in Autism Spectrum Disorder (ASD), sponsored by Fenix Innovation Group. Started Apr 2021; status: completed.
02
Drugs
NTI164
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05516407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516407.